New drug shows promise for rare inflammatory disease
NCT ID NCT04602598
First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This study tested the drug zanubrutinib in 10 people with IgG4-related disease, a condition that causes swelling in glands and other organs. The goal was to see if the drug could reduce gland size and inflammation over 24 weeks. Researchers measured changes using PET-MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Palo Alto, California, 94304, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib
What this could lead to
If successful, this could point toward a new treatment option for IgG4-related disease, reducing gland swelling and inflammation.
What could go wrong
This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.